LONDON, Aug. 5, 2013 /PRNewswire/ -- Lightlake
Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a
biopharmaceutical company developing addiction treatments based on
its expertise in opioid antagonists, announced today that it has
retained KCSA Strategic Communications ("KCSA"), a leading
New York-based communications
firm, to direct the Company's investor and public relations
programs.
KCSA will deploy an integrated investor and public relations
campaign to increase awareness of Lightlake and its treatments for
Binge Eating Disorder ("BED"), for Bulimia Nervosa ("BN"), and for
the complications of drug addiction. The campaign will focus on the
various influencers in the healthcare sector, in addition to
outreach to business and key trade publications.
KCSA has garnered a strong reputation through four decades of
experience representing domestic and international companies across
all industries, including healthcare services and
biopharmaceuticals. Managing Partners Todd Fromer and Lewis Goldberg will head up the account and
provide strategic guidance on financial and media
communication.
"We understand the importance of a proactive communications
program to effectively reach the investment community, our
shareholders, and the appropriate media. As we continue to grow our
business and develop modern treatments for addiction diseases, we
look forward to working closely with KCSA to effectively
communicate our growth potential. We have exciting treatments in
our pipeline that are in advanced stage clinical trials, providing
us with significant short-term and long-term opportunities that can
act as catalysts for our business. With KCSA's guidance, we hope to
highlight the ongoing development of these treatments to our
shareholders and the potential value they could have upon receiving
regulatory market clearance," said Dr. Roger Crystal, Chief Executive Officer of
Lightlake.
"We believe our experience with other biopharmaceutical
companies and subsequent success with providing an integrated
communications platform makes KCSA uniquely qualified to
communicate Lightlake's growth potential," said Mr. Fromer.
"Addiction affects millions of people and their families in
the United States alone, and we
are enthusiastic about increasing awareness of Lightlake and its
treatment pipeline."
To be added to the Lightlake Therapeutics investor email list,
please email pcarlson@kcsa.com with LLTP in the subject
line.
About Lightlake Therapeutics
Lightlake Therapeutics
Inc., a London-based
biopharmaceutical company, is using its expertise in opioid
antagonists to build a platform of innovative solutions to common
addictions and related disorders. The Company holds patents
covering the use of intranasal naloxone to treat Binge Eating
Disorder ("BED") as well as patents covering addiction to drugs
including cocaine, amphetamine, and MDMA. Lightlake is currently
focused on advancing its treatment for BED, which has successfully
completed Phase II clinical trials, and a Phase II trial is planned
for the indication of Bulimia Nervosa. Lightlake is also applying
its technology to develop a treatment for managing the
complications of opioid drug addiction in collaboration with the
National Institute on Drug Abuse (NIDA), part of the National
Institutes of Health. For more information please visit:
http://www.lightlaketherapeutics.com
About KCSA Strategic Communications
KCSA is a
fully-integrated communications agency specializing in public
relations, investor relations and marketing with expertise in
financial and professional services, technology, healthcare, media,
energy and public services companies. Since 1969, the firm has
demonstrated strategic thinking and program execution that drives
results for its clients in the ever-changing communications and
digital landscape. The firm's clients are its best references. For
more information, please visit www.kcsa.com.
Investor Relations Contact:
Phil Carlson / Josh
Dver
KCSA Strategic Communications
212-896-1233 / 212-896-1239
pcarlson@kcsa.com / jdver@kcsa.com
Public Relations Contact:
Anne
Donohoe / Taylor McGrann
KCSA Strategic Communications
212-896-1261 / 212-896-1253
adonohoe@kcsa.com / tmcgrann@kcsa.com
SOURCE Lightlake Therapeutics Inc.